FUTURES EXPO SERIES
RNAfold . AI
AI-assisted ribonucleic acid ( RNA ) -targeting drug discovery and design
Co-locator
RNAfold . AI addresses the significant challenge of developing RNA-targeting drugs . It is a process hindered by the complex folding of RNAs and unknown binding partners . Current methods rely on trial and error , screening thousands of compounds with limited predictive success , often leading to failures in later stages due to toxicity or lack of efficacy .
RNAfold . AI leverages cutting-edge AI algorithms to predict RNA-targeting drugs with high accuracy . By training on comprehensive structural data of target RNAs and potential drug compounds , including binding experiments and toxicity profiles , its AI models can efficiently identify promising drug leads .
The company has developed unique training datasets from databases , literature , and experimental data , resulting in an AI platform that predicts successful drugs with 100 times more accuracy . Currently in the proof-of-concept stage , RNAfold . AI aims to revolutionise RNA therapeutics by enhancing discovery , design , and development processes , targeting both out-licensing drug leads and in-house clinical development .
Key capabilities
> AI > RNA therapeutics design
Differentiators
> Unique datasets > Specialised AI models > Novel RNA-targeting drugs
Key customers > Pharma and biotech companies
Key partnerships > UNSW RNA Institute
rnafold . ai
18 •